[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589253":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":46,"responsibleParty":154,"collaborators":25,"id":156,"slug":157,"hasResults":158,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":25,"eligibilityCriteria":162,"healthyVolunteers":158,"sex":163,"minAge":164,"maxAge":25,"enrollmentInfo":165,"targetDuration":25,"studyType":168,"phases":169,"briefSummary":171,"conditions":172,"keywords":177,"overallStatus":49,"whyStopped":25,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},{"fullName":5,"class":6},"Exelixis","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation Phase","EXPERIMENTAL","Participants with recurrent advanced or metastatic solid tumors will receive escalating dose levels doses of XB628 as a single agent and in combination with zanzalintinib.",[13,14],"Biological: XB628","Drug: Zanzalintinib",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose Expansion","Participants with recurrent advanced or metastatic solid tumors will receive XB628 as a single agent and in combination with zanzalintinib.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","XB628","Intravenous infusion(s)",[9,16],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Zanzalintinib","Oral tablet(s)",[9,16],[32],"XL092",[34],{"name":35,"affiliation":5,"role":36},"Medical Director","STUDY_DIRECTOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":25,"email":42},"Exelixis Clinical Trials","CONTACT","1-888-EXELIXIS (888-393-5494)","druginfo@exelixis.com",{"name":44,"role":40,"phone":45,"phoneExt":25,"email":25},"Backup or International","650-837-7400",[47,61,71,81,91,96,106,115,125,135,145],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":25},"Exelixis Clinical Site #5","RECRUITING","San Francisco","California","94158","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-122.41942,37.77493,{"lat":59,"lon":58},{"facility":62,"status":49,"city":63,"state":64,"zip":65,"country":53,"countryCode":54,"cosmosGeoPoint":66,"geoPoint":70,"contacts":25},"Exelixis Clinical Site #4","New Haven","Connecticut","06520",{"type":56,"coordinates":67},[68,69],-72.92816,41.30815,{"lat":69,"lon":68},{"facility":72,"status":49,"city":73,"state":74,"zip":75,"country":53,"countryCode":54,"cosmosGeoPoint":76,"geoPoint":80,"contacts":25},"Exelixis Clinical Site #8","Tampa","Florida","33612",{"type":56,"coordinates":77},[78,79],-82.45843,27.94752,{"lat":79,"lon":78},{"facility":82,"status":49,"city":83,"state":84,"zip":85,"country":53,"countryCode":54,"cosmosGeoPoint":86,"geoPoint":90,"contacts":25},"Exelixis Clinical Site #10","Boston","Massachusetts","02114",{"type":56,"coordinates":87},[88,89],-71.05977,42.35843,{"lat":89,"lon":88},{"facility":92,"status":49,"city":83,"state":84,"zip":85,"country":53,"countryCode":54,"cosmosGeoPoint":93,"geoPoint":95,"contacts":25},"Exelixis Clinical Site #11",{"type":56,"coordinates":94},[88,89],{"lat":89,"lon":88},{"facility":97,"status":49,"city":98,"state":99,"zip":100,"country":53,"countryCode":54,"cosmosGeoPoint":101,"geoPoint":105,"contacts":25},"Exelixis Clinical Site #6","St Louis","Missouri","63108",{"type":56,"coordinates":102},[103,104],-90.19789,38.62727,{"lat":104,"lon":103},{"facility":107,"status":49,"city":108,"state":108,"zip":109,"country":53,"countryCode":54,"cosmosGeoPoint":110,"geoPoint":114,"contacts":25},"Exelixis Clinical Site #7","New York","10029",{"type":56,"coordinates":111},[112,113],-74.00597,40.71427,{"lat":113,"lon":112},{"facility":116,"status":49,"city":117,"state":118,"zip":119,"country":53,"countryCode":54,"cosmosGeoPoint":120,"geoPoint":124,"contacts":25},"Exelixis Clinical Site #1","Hickory","North Carolina","28602",{"type":56,"coordinates":121},[122,123],-81.3412,35.73319,{"lat":123,"lon":122},{"facility":126,"status":49,"city":127,"state":128,"zip":129,"country":53,"countryCode":54,"cosmosGeoPoint":130,"geoPoint":134,"contacts":25},"Exelixis Clinical Site #3","Nashville","Tennessee","37203",{"type":56,"coordinates":131},[132,133],-86.78444,36.16589,{"lat":133,"lon":132},{"facility":136,"status":49,"city":137,"state":138,"zip":139,"country":53,"countryCode":54,"cosmosGeoPoint":140,"geoPoint":144,"contacts":25},"Exelixis Clinical Site #9","Houston","Texas","77030",{"type":56,"coordinates":141},[142,143],-95.36327,29.76328,{"lat":143,"lon":142},{"facility":146,"status":49,"city":147,"state":138,"zip":148,"country":53,"countryCode":54,"cosmosGeoPoint":149,"geoPoint":153,"contacts":25},"Exelixis Clinical Site #2","San Antonio","78229",{"type":56,"coordinates":150},[151,152],-98.49363,29.42412,{"lat":152,"lon":151},{"type":155,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100589253","phase-1-a-study-of-xb628-alone-and-in-combination-with-zanzalintinib-in-participants-with-recurrent-advanced-or-metastatic-solid-tumors-100589253",false,"NCT06952010","A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors","A Phase 1 Dose Escalation and Expansion Study of XB628 as a Single Agent and in Combination With Zanzalintinib in Participants With Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Minimum life expectancy of ≥ 12 weeks.\n* Have a recurrent advanced or metastatic solid tumor that is histologically or cytologically confirmed.\n* Adequate organ and marrow function.\n* Not amenable to curative treatment with surgery or radiation.\n* Received at least 1 line of prior systemic anticancer therapy in the recurrent or metastatic setting.\n* Acceptable alternative therapy was received, refused, intolerable, or no longer effective.\n* Capable of understanding and complying with the protocol requirements and provide signed informed consent according to the protocol and local requirements.\n\nKey Exclusion Criteria\n\n* Primary brain tumors or known active brain metastases.\n* Major surgery (eg, gastrointestinal surgery, removal or biopsy of brain metastasis) within 4 weeks before the first dose of study treatment.\n* Received radiation therapy within 1 week before the first dose of study treatment or clinically relevant ongoing complications from prior radiation therapy.\n* Received prior therapy targeting NK cells (eg, monalizumab).\n* A woman of childbearing potential has a positive serum pregnancy test within 7 days prior to study treatment.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":166,"type":167},303,"ESTIMATED","INTERVENTIONAL",[170],"PHASE1","This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and\u002For recommended dosage(s) for expansion (RDE\\[s\\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.",[173,174,175,176],"Solid Tumor","Advanced Solid Tumor","Metastatic Solid Tumor","Immune Sensitive Tumor",[22,178,179,180,181,182,28],"Solid tumor","Advanced solid tumor","Metastatic solid tumor","Immune sensitive tumor","PD-L1","2026-06-19",{"date":185,"type":186},"2026-06-24","ACTUAL",{"date":188,"type":186},"2025-05-01",{"date":190,"type":167},"2027-11-30",{"name":5,"class":6},11]